Cargando…

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases

Epigenetic mechanisms, especially DNA methylation and histone modifications, are dynamic processes that regulate the gene expression transcriptional program in normal and diseased states. The bromodomain and extraterminal (BET) protein family (BRD2, BRD3, BRD4, and BRDT) are epigenetic readers that,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgado-Pascual, Jose Luis, Rayego-Mateos, Sandra, Tejedor, Lucia, Suarez-Alvarez, Beatriz, Ruiz-Ortega, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857099/ https://www.ncbi.nlm.nih.gov/pubmed/31780938 http://dx.doi.org/10.3389/fphar.2019.01315

Ejemplares similares

Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology
por: Morgado-Pascual, Jose Luis, et al.
Publicado: (2018)

Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2
por: Doherty, Joanne, et al.
Publicado: (2022)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis
por: Tejedor-Santamaria, Lucia, et al.
Publicado: (2022)

Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis
por: Morgado-Pascual, José Luis, et al.
Publicado: (2022)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease
por: Rayego-Mateos, Sandra, et al.
Publicado: (2023)

Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
por: Chen, Ye, et al.
Publicado: (2019)

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation
por: Stock, Carmel J. W., et al.
Publicado: (2019)

Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours
por: Mu, Jianfeng, et al.
Publicado: (2020)

Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma
por: Vichaikul, Sirapa, et al.
Publicado: (2022)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer’s Disease
por: Matuszewska, Marta, et al.
Publicado: (2022)

Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps
por: Keck, Kristin M., et al.
Publicado: (2017)

Inflammatory and Fibrotic Mediators in Renal Diseases
por: Rayego-Mateos, Sandra, et al.
Publicado: (2019)

The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells
por: Pan, Hanyu, et al.
Publicado: (2017)

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation
por: Colardo, Mayra, et al.
Publicado: (2023)

Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy
por: Gargano, Deborah, et al.
Publicado: (2023)

Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC
por: Lee, Jang Hyuck, et al.
Publicado: (2021)

Bisphenol A Modulates Autophagy and Exacerbates Chronic Kidney Damage in Mice
por: Priego, Alberto Ruiz, et al.
Publicado: (2021)

Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration
por: Liu, Chen, et al.
Publicado: (2019)

Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis
por: Marquez-Exposito, Laura, et al.
Publicado: (2018)

Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
por: Chang Muñoz, Meilen, et al.
Publicado: (2020)

Acute Kidney Injury is Aggravated in Aged Mice by the Exacerbation of Proinflammatory Processes
por: Marquez-Exposito, Laura, et al.
Publicado: (2021)

Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells
por: Morgado-Pascual, Jose L., et al.
Publicado: (2015)

CCN2 Binds to Tubular Epithelial Cells in the Kidney
por: Rayego-Mateos, Sandra, et al.
Publicado: (2022)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study
por: Moreno, Victor, et al.
Publicado: (2022)

CCN2 Increases TGF-β Receptor Type II Expression in Vascular Smooth Muscle Cells: Essential Role of CCN2 in the TGF-β Pathway Regulation
por: Tejera-Muñoz, Antonio, et al.
Publicado: (2021)

Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
por: Rayego-Mateos, Sandra, et al.
Publicado: (2018)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models
por: Liu, Xin-Mo, et al.
Publicado: (2023)

Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes
por: Lin, Zhirong, et al.
Publicado: (2022)

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
por: Borthakur, Gautam, et al.
Publicado: (2021)

Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter‐balanced by a strong Th2 bias
por: Dalloul, Zeinab, et al.
Publicado: (2021)

Mitochondrial Dysfunction in the Cardio-Renal Axis
por: Mendez-Barbero, Nerea, et al.
Publicado: (2023)

Vitamin D, Cellular Senescence and Chronic Kidney Diseases: What Is Missing in the Equation?
por: Martinelli, Romina P., et al.
Publicado: (2023)

CCN2 Activates RIPK3, NLRP3 Inflammasome, and NRF2/Oxidative Pathways Linked to Kidney Inflammation
por: Rayego-Mateos, Sandra, et al.
Publicado: (2023)

Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia
por: Baragaño Raneros, Aroa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_42l5e7jvljulqam137oh1utb8p